Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PEOPLE - The National Institute for Health and Clinical Excellence (NICE) makes appointment:

This article was originally published in Clinica

Executive Summary

The National Institute for Health and Clinical Excellence (NICE) has appointed Shah Ebrahim and Jenny Griffiths to the board, to help meet the increased demand placed on it since incorporating the preventive health roles of the Health Development Agency, last April. Professor Ebrahim this month takes up a new post at the London School of Hygiene and Tropical Medicine, as professor of public health. He is also co-ordinating editor of the Cochrane Heart Group and a consultant to the World Health Organization. Until last year, he chaired the NHS R&D Health Technology Assessment commissioning board. Ms Griffiths is a senior strategic manager with 11 years' experience as CEO of an NHS health authority, most recently at West Surrey.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT056804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel